Today
+1.00%
5 Days
+4.37%
1 Month
-6.43%
6 Months
+28.83%
Year to Date
+8.87%
1 Year
+55.82%
• Moderna stock rose due to positive Phase 3 oncology trial results and upcoming congress presentations. • FDA approval of updated COVID-19 vaccines and capital-raising initiatives reinforced institutional financial confidence. • Moderna reported annual revenue of $1.94 billion and a net loss of $2.82 billion.
• Novo Nordisk faced downward pressure after its Capital Markets Day strategic update. • Eli Lilly competition and patent expirations raised concerns over market dominance. • The MACD value of negative 0.874 indicates a sell signal.
• Macroeconomic tailwinds and risk-on sentiment drove Moderna's strong upward rally and volatility. • Positive late-stage clinical data for intismeran expanded valuation expectations for oncology. • Analyst upgrades and institutional demand absorbed selling pressure from routine insider sales.
• Novo Nordisk partnered with Orbis Medicine for AI-driven oral cardiometabolic drug discovery. • European regulators issued a favorable marketing recommendation for Frehemgo in hemophilia A. • The company reported $46.70B in annual revenue and $15.48B in net profit.
• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.
• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.


| Shareholders | Proportion |
|---|---|
| Lilly Endowment, Inc. | 9.76% |
| Vanguard Capital Management, LLC | 5.67% |
| PNC Investments LLC | 5.43% |
| BlackRock Institutional Trust Company, N.A. | 4.44% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 46.65% |
| Investment Advisor/Hedge Fund | 19.18% |
| Foundation | 9.76% |
| Research Firm | 2.14% |
Related Instruments